Synergistic effects of isomorellin and forbesione with doxorubicin on apoptosis induction in human cholangiocarcinoma cell lines

Background Chemotherapy for advanced cholangiocarcinoma (CCA) is largely ineffective, but innovative combinations of chemotherapeutic agents and natural compounds represent a promising strategy. In our previous studies, isomorellin and forbesione, caged xanthones isolated from Garcinia hanburyi , we...

Full description

Saved in:
Bibliographic Details
Published inCancer cell international Vol. 14; no. 1; p. 68
Main Authors Hahnvajanawong, Chariya, Wattanawongdon, Wareeporn, Chomvarin, Chariya, Anantachoke, Natthinee, Kanthawong, Sakawrat, Sripa, Banchob, Reutrakul, Vichai
Format Journal Article
LanguageEnglish
Published London BioMed Central 24.10.2014
BioMed Central Ltd
Subjects
Online AccessGet full text
ISSN1475-2867
1475-2867
DOI10.1186/1475-2867-14-68

Cover

Abstract Background Chemotherapy for advanced cholangiocarcinoma (CCA) is largely ineffective, but innovative combinations of chemotherapeutic agents and natural compounds represent a promising strategy. In our previous studies, isomorellin and forbesione, caged xanthones isolated from Garcinia hanburyi , were found to induce cell cycle arrest and apoptosis in CCA cell lines. The subject of our inquiry is the synergistic effect(s) of these caged xanthones with doxorubicin on growth inhibition and apoptosis induction in human CCA cell lines. Methods KKU-100, KKU-M139 and KKU-M156 cell lines and Chang cells were treated with either isomorellin or forbesione alone or in combination with doxorubicin. Cell viability was determined using the sulforhodamine B assay. The combined effects of plant compounds with doxorubicin were analyzed using the isobologram and combination index method of Chou-Talalay. Apoptosis was determined by ethidium bromide/acridine orange staining. Protein expressions were determined by Western blot analysis. Results Isomorellin or forbesione alone inhibited the growth of these CCA cell lines in a dose-dependent manner and showed selective cytotoxicity against CCA cells but not against Chang cells. Isomorellin/doxorubicin combination showed a synergistic growth inhibitory effect on KKU-M139 and KKU-M156 cells, while the forbesione/doxorubicin combination showed a synergistic growth inhibitory effect on KKU-100 and KKU-M139 cells. The percentages of apoptotic cells were significantly higher in the combined treatments than in the respective single drug treatments. The combined treatments strongly enhanced the expression of Bax/Bcl-2, activated caspase-9 and caspase-3, while suppressing the expression of survivin, procaspase-9 and procaspase-3, compared with single drug treatments. The degree of suppression of NF-κB activation mediated by a decrease in the expression of NF-κB/p65, a reduction of the pIκB-α level and an increase in the IκB-α protein level, was significantly higher in the combined treatment groups than in the single drug treatment groups. The degree of suppression of MRP1 protein expression was also significantly higher in the combined treatment than in the single drug treatment groups. Conclusion The combinations of isomorellin/doxorubicin and forbesione/doxorubicin showed significant synergistic effects on the growth inhibition and apoptosis induction in KKU-M156 and KKU-100 cells. Caged xanthones may be useful adjunct treatments with chemotherapy for Opisthorchis viverrini (OV)-associated CCA.
AbstractList Chemotherapy for advanced cholangiocarcinoma (CCA) is largely ineffective, but innovative combinations of chemotherapeutic agents and natural compounds represent a promising strategy. In our previous studies, isomorellin and forbesione, caged xanthones isolated from Garcinia hanburyi, were found to induce cell cycle arrest and apoptosis in CCA cell lines. The subject of our inquiry is the synergistic effect(s) of these caged xanthones with doxorubicin on growth inhibition and apoptosis induction in human CCA cell lines.BACKGROUNDChemotherapy for advanced cholangiocarcinoma (CCA) is largely ineffective, but innovative combinations of chemotherapeutic agents and natural compounds represent a promising strategy. In our previous studies, isomorellin and forbesione, caged xanthones isolated from Garcinia hanburyi, were found to induce cell cycle arrest and apoptosis in CCA cell lines. The subject of our inquiry is the synergistic effect(s) of these caged xanthones with doxorubicin on growth inhibition and apoptosis induction in human CCA cell lines.KKU-100, KKU-M139 and KKU-M156 cell lines and Chang cells were treated with either isomorellin or forbesione alone or in combination with doxorubicin. Cell viability was determined using the sulforhodamine B assay. The combined effects of plant compounds with doxorubicin were analyzed using the isobologram and combination index method of Chou-Talalay. Apoptosis was determined by ethidium bromide/acridine orange staining. Protein expressions were determined by Western blot analysis.METHODSKKU-100, KKU-M139 and KKU-M156 cell lines and Chang cells were treated with either isomorellin or forbesione alone or in combination with doxorubicin. Cell viability was determined using the sulforhodamine B assay. The combined effects of plant compounds with doxorubicin were analyzed using the isobologram and combination index method of Chou-Talalay. Apoptosis was determined by ethidium bromide/acridine orange staining. Protein expressions were determined by Western blot analysis.Isomorellin or forbesione alone inhibited the growth of these CCA cell lines in a dose-dependent manner and showed selective cytotoxicity against CCA cells but not against Chang cells. Isomorellin/doxorubicin combination showed a synergistic growth inhibitory effect on KKU-M139 and KKU-M156 cells, while the forbesione/doxorubicin combination showed a synergistic growth inhibitory effect on KKU-100 and KKU-M139 cells. The percentages of apoptotic cells were significantly higher in the combined treatments than in the respective single drug treatments. The combined treatments strongly enhanced the expression of Bax/Bcl-2, activated caspase-9 and caspase-3, while suppressing the expression of survivin, procaspase-9 and procaspase-3, compared with single drug treatments. The degree of suppression of NF-κB activation mediated by a decrease in the expression of NF-κB/p65, a reduction of the pIκB-α level and an increase in the IκB-α protein level, was significantly higher in the combined treatment groups than in the single drug treatment groups. The degree of suppression of MRP1 protein expression was also significantly higher in the combined treatment than in the single drug treatment groups.RESULTSIsomorellin or forbesione alone inhibited the growth of these CCA cell lines in a dose-dependent manner and showed selective cytotoxicity against CCA cells but not against Chang cells. Isomorellin/doxorubicin combination showed a synergistic growth inhibitory effect on KKU-M139 and KKU-M156 cells, while the forbesione/doxorubicin combination showed a synergistic growth inhibitory effect on KKU-100 and KKU-M139 cells. The percentages of apoptotic cells were significantly higher in the combined treatments than in the respective single drug treatments. The combined treatments strongly enhanced the expression of Bax/Bcl-2, activated caspase-9 and caspase-3, while suppressing the expression of survivin, procaspase-9 and procaspase-3, compared with single drug treatments. The degree of suppression of NF-κB activation mediated by a decrease in the expression of NF-κB/p65, a reduction of the pIκB-α level and an increase in the IκB-α protein level, was significantly higher in the combined treatment groups than in the single drug treatment groups. The degree of suppression of MRP1 protein expression was also significantly higher in the combined treatment than in the single drug treatment groups.The combinations of isomorellin/doxorubicin and forbesione/doxorubicin showed significant synergistic effects on the growth inhibition and apoptosis induction in KKU-M156 and KKU-100 cells. Caged xanthones may be useful adjunct treatments with chemotherapy for Opisthorchis viverrini (OV)-associated CCA.CONCLUSIONThe combinations of isomorellin/doxorubicin and forbesione/doxorubicin showed significant synergistic effects on the growth inhibition and apoptosis induction in KKU-M156 and KKU-100 cells. Caged xanthones may be useful adjunct treatments with chemotherapy for Opisthorchis viverrini (OV)-associated CCA.
BACKGROUND: Chemotherapy for advanced cholangiocarcinoma (CCA) is largely ineffective, but innovative combinations of chemotherapeutic agents and natural compounds represent a promising strategy. In our previous studies, isomorellin and forbesione, caged xanthones isolated from Garcinia hanburyi, were found to induce cell cycle arrest and apoptosis in CCA cell lines. The subject of our inquiry is the synergistic effect(s) of these caged xanthones with doxorubicin on growth inhibition and apoptosis induction in human CCA cell lines. METHODS: KKU-100, KKU-M139 and KKU-M156 cell lines and Chang cells were treated with either isomorellin or forbesione alone or in combination with doxorubicin. Cell viability was determined using the sulforhodamine B assay. The combined effects of plant compounds with doxorubicin were analyzed using the isobologram and combination index method of Chou-Talalay. Apoptosis was determined by ethidium bromide/acridine orange staining. Protein expressions were determined by Western blot analysis. RESULTS: Isomorellin or forbesione alone inhibited the growth of these CCA cell lines in a dose-dependent manner and showed selective cytotoxicity against CCA cells but not against Chang cells. Isomorellin/doxorubicin combination showed a synergistic growth inhibitory effect on KKU-M139 and KKU-M156 cells, while the forbesione/doxorubicin combination showed a synergistic growth inhibitory effect on KKU-100 and KKU-M139 cells. The percentages of apoptotic cells were significantly higher in the combined treatments than in the respective single drug treatments. The combined treatments strongly enhanced the expression of Bax/Bcl-2, activated caspase-9 and caspase-3, while suppressing the expression of survivin, procaspase-9 and procaspase-3, compared with single drug treatments. The degree of suppression of NF-κB activation mediated by a decrease in the expression of NF-κB/p65, a reduction of the pIκB-α level and an increase in the IκB-α protein level, was significantly higher in the combined treatment groups than in the single drug treatment groups. The degree of suppression of MRP1 protein expression was also significantly higher in the combined treatment than in the single drug treatment groups. CONCLUSION: The combinations of isomorellin/doxorubicin and forbesione/doxorubicin showed significant synergistic effects on the growth inhibition and apoptosis induction in KKU-M156 and KKU-100 cells. Caged xanthones may be useful adjunct treatments with chemotherapy for Opisthorchis viverrini (OV)-associated CCA.
Doc number: 68 Abstract Background: Chemotherapy for advanced cholangiocarcinoma (CCA) is largely ineffective, but innovative combinations of chemotherapeutic agents and natural compounds represent a promising strategy. In our previous studies, isomorellin and forbesione, caged xanthones isolated from Garcinia hanburyi , were found to induce cell cycle arrest and apoptosis in CCA cell lines. The subject of our inquiry is the synergistic effect(s) of these caged xanthones with doxorubicin on growth inhibition and apoptosis induction in human CCA cell lines. Methods: KKU-100, KKU-M139 and KKU-M156 cell lines and Chang cells were treated with either isomorellin or forbesione alone or in combination with doxorubicin. Cell viability was determined using the sulforhodamine B assay. The combined effects of plant compounds with doxorubicin were analyzed using the isobologram and combination index method of Chou-Talalay. Apoptosis was determined by ethidium bromide/acridine orange staining. Protein expressions were determined by Western blot analysis. Results: Isomorellin or forbesione alone inhibited the growth of these CCA cell lines in a dose-dependent manner and showed selective cytotoxicity against CCA cells but not against Chang cells. Isomorellin/doxorubicin combination showed a synergistic growth inhibitory effect on KKU-M139 and KKU-M156 cells, while the forbesione/doxorubicin combination showed a synergistic growth inhibitory effect on KKU-100 and KKU-M139 cells. The percentages of apoptotic cells were significantly higher in the combined treatments than in the respective single drug treatments. The combined treatments strongly enhanced the expression of Bax/Bcl-2, activated caspase-9 and caspase-3, while suppressing the expression of survivin, procaspase-9 and procaspase-3, compared with single drug treatments. The degree of suppression of NF-κB activation mediated by a decrease in the expression of NF-κB/p65, a reduction of the pIκB-α level and an increase in the IκB-α protein level, was significantly higher in the combined treatment groups than in the single drug treatment groups. The degree of suppression of MRP1 protein expression was also significantly higher in the combined treatment than in the single drug treatment groups. Conclusion: The combinations of isomorellin/doxorubicin and forbesione/doxorubicin showed significant synergistic effects on the growth inhibition and apoptosis induction in KKU-M156 and KKU-100 cells. Caged xanthones may be useful adjunct treatments with chemotherapy for Opisthorchis viverrini (OV)-associated CCA.
Chemotherapy for advanced cholangiocarcinoma (CCA) is largely ineffective, but innovative combinations of chemotherapeutic agents and natural compounds represent a promising strategy. In our previous studies, isomorellin and forbesione, caged xanthones isolated from Garcinia hanburyi, were found to induce cell cycle arrest and apoptosis in CCA cell lines. The subject of our inquiry is the synergistic effect(s) of these caged xanthones with doxorubicin on growth inhibition and apoptosis induction in human CCA cell lines. KKU-100, KKU-M139 and KKU-M156 cell lines and Chang cells were treated with either isomorellin or forbesione alone or in combination with doxorubicin. Cell viability was determined using the sulforhodamine B assay. The combined effects of plant compounds with doxorubicin were analyzed using the isobologram and combination index method of Chou-Talalay. Apoptosis was determined by ethidium bromide/acridine orange staining. Protein expressions were determined by Western blot analysis. Isomorellin or forbesione alone inhibited the growth of these CCA cell lines in a dose-dependent manner and showed selective cytotoxicity against CCA cells but not against Chang cells. Isomorellin/doxorubicin combination showed a synergistic growth inhibitory effect on KKU-M139 and KKU-M156 cells, while the forbesione/doxorubicin combination showed a synergistic growth inhibitory effect on KKU-100 and KKU-M139 cells. The percentages of apoptotic cells were significantly higher in the combined treatments than in the respective single drug treatments. The combined treatments strongly enhanced the expression of Bax/Bcl-2, activated caspase-9 and caspase-3, while suppressing the expression of survivin, procaspase-9 and procaspase-3, compared with single drug treatments. The degree of suppression of NF-κB activation mediated by a decrease in the expression of NF-κB/p65, a reduction of the pIκB-α level and an increase in the IκB-α protein level, was significantly higher in the combined treatment groups than in the single drug treatment groups. The degree of suppression of MRP1 protein expression was also significantly higher in the combined treatment than in the single drug treatment groups. The combinations of isomorellin/doxorubicin and forbesione/doxorubicin showed significant synergistic effects on the growth inhibition and apoptosis induction in KKU-M156 and KKU-100 cells. Caged xanthones may be useful adjunct treatments with chemotherapy for Opisthorchis viverrini (OV)-associated CCA.
Background Chemotherapy for advanced cholangiocarcinoma (CCA) is largely ineffective, but innovative combinations of chemotherapeutic agents and natural compounds represent a promising strategy. In our previous studies, isomorellin and forbesione, caged xanthones isolated from Garcinia hanburyi , were found to induce cell cycle arrest and apoptosis in CCA cell lines. The subject of our inquiry is the synergistic effect(s) of these caged xanthones with doxorubicin on growth inhibition and apoptosis induction in human CCA cell lines. Methods KKU-100, KKU-M139 and KKU-M156 cell lines and Chang cells were treated with either isomorellin or forbesione alone or in combination with doxorubicin. Cell viability was determined using the sulforhodamine B assay. The combined effects of plant compounds with doxorubicin were analyzed using the isobologram and combination index method of Chou-Talalay. Apoptosis was determined by ethidium bromide/acridine orange staining. Protein expressions were determined by Western blot analysis. Results Isomorellin or forbesione alone inhibited the growth of these CCA cell lines in a dose-dependent manner and showed selective cytotoxicity against CCA cells but not against Chang cells. Isomorellin/doxorubicin combination showed a synergistic growth inhibitory effect on KKU-M139 and KKU-M156 cells, while the forbesione/doxorubicin combination showed a synergistic growth inhibitory effect on KKU-100 and KKU-M139 cells. The percentages of apoptotic cells were significantly higher in the combined treatments than in the respective single drug treatments. The combined treatments strongly enhanced the expression of Bax/Bcl-2, activated caspase-9 and caspase-3, while suppressing the expression of survivin, procaspase-9 and procaspase-3, compared with single drug treatments. The degree of suppression of NF-κB activation mediated by a decrease in the expression of NF-κB/p65, a reduction of the pIκB-α level and an increase in the IκB-α protein level, was significantly higher in the combined treatment groups than in the single drug treatment groups. The degree of suppression of MRP1 protein expression was also significantly higher in the combined treatment than in the single drug treatment groups. Conclusion The combinations of isomorellin/doxorubicin and forbesione/doxorubicin showed significant synergistic effects on the growth inhibition and apoptosis induction in KKU-M156 and KKU-100 cells. Caged xanthones may be useful adjunct treatments with chemotherapy for Opisthorchis viverrini (OV)-associated CCA.
Author Kanthawong, Sakawrat
Hahnvajanawong, Chariya
Reutrakul, Vichai
Chomvarin, Chariya
Wattanawongdon, Wareeporn
Sripa, Banchob
Anantachoke, Natthinee
Author_xml – sequence: 1
  givenname: Chariya
  surname: Hahnvajanawong
  fullname: Hahnvajanawong, Chariya
  email: hchari@kku.ac.th
  organization: Department of Microbiology, Center of Excellence for Innovation in Chemistry, Faculty of Medicine, Khon Kaen University, Liver Fluke and Cholangiocarcinoma Research Center, Khon Kaen University
– sequence: 2
  givenname: Wareeporn
  surname: Wattanawongdon
  fullname: Wattanawongdon, Wareeporn
  organization: Department of Microbiology, Center of Excellence for Innovation in Chemistry, Faculty of Medicine, Khon Kaen University, Liver Fluke and Cholangiocarcinoma Research Center, Khon Kaen University
– sequence: 3
  givenname: Chariya
  surname: Chomvarin
  fullname: Chomvarin, Chariya
  organization: Department of Microbiology, Center of Excellence for Innovation in Chemistry, Faculty of Medicine, Khon Kaen University, Liver Fluke and Cholangiocarcinoma Research Center, Khon Kaen University
– sequence: 4
  givenname: Natthinee
  surname: Anantachoke
  fullname: Anantachoke, Natthinee
  organization: Department of Pharmacognosy, Faculty of Pharmacy, Mahidol University
– sequence: 5
  givenname: Sakawrat
  surname: Kanthawong
  fullname: Kanthawong, Sakawrat
  organization: Department of Microbiology, Center of Excellence for Innovation in Chemistry, Faculty of Medicine, Khon Kaen University
– sequence: 6
  givenname: Banchob
  surname: Sripa
  fullname: Sripa, Banchob
  organization: Department of Pathology, Faculty of Medicine, Khon Kaen University
– sequence: 7
  givenname: Vichai
  surname: Reutrakul
  fullname: Reutrakul, Vichai
  organization: Department of Chemistry, Faculty of Science, Mahidol University
BackLink https://www.ncbi.nlm.nih.gov/pubmed/25866479$$D View this record in MEDLINE/PubMed
BookMark eNp1kk1v1DAQhi1URD_gzA1Z4sIl1PY6tnNBgoovqRIH4Gw5jrPrKvEsdlLojZ_ORNtW24o9eex55vXrGZ-SowQpEPKSs7ecG3XOpa4rYZSuuKyUeUJO7k-O9uJjclrKFWNcG8WekWNRG6Wkbk7I3-83KeR1LFP0NPR98FOh0NNYYIQchiEm6lJHe8htKBFvp7_jtKEd_IE8t9FjHhDZwnaCEguNqZv9hCBGdDOPLlG_gcGldQTvMvIwOupRmaJ2KM_J094NJby4Xc_Iz08ff1x8qS6_ff568f6yapUQUxUapjtWM-l445XomRCd16yRK6NlrXBfa4n5TgVpZNO7TvOGe9GpxgXWy9UZebfT3c7tGDof0pTdYLc5ji7fWHDRPsykuLFruLZy1QijDQp82Am0EQ4IPMx4GO0yAbtMACOrFpE3ty4y_JpDmewYy9IMlwLMxXKlV0ybWtSIvn6EXsGcE_YIKSGaWhnDkHq1_6x7O3cTRqDeAT5DKTn01sfJLQNCk3GwnNnlJ_3H6fmjujvpwxVsV1GQTOuQ9wwfKPkHCpDcYA
CitedBy_id crossref_primary_10_3389_fonc_2022_850732
crossref_primary_10_3390_app15031125
crossref_primary_10_3390_cells9020498
crossref_primary_10_3389_fonc_2022_834072
crossref_primary_10_1016_j_biopha_2022_113610
crossref_primary_10_1016_j_jconrel_2020_02_018
crossref_primary_10_1021_acs_jnatprod_9b00018
crossref_primary_10_15212_AMM_2022_0001
crossref_primary_10_2174_0113816128286282240405064210
crossref_primary_10_1016_j_clinre_2017_12_006
crossref_primary_10_1152_ajpcell_00176_2024
crossref_primary_10_1055_a_1676_9678
crossref_primary_10_1177_1534735420911430
crossref_primary_10_1007_s13596_017_0278_6
crossref_primary_10_3892_ol_2016_5284
crossref_primary_10_1016_j_bbadis_2017_06_005
crossref_primary_10_1039_D1FO03542H
Cites_doi 10.1016/S0968-0004(00)01617-0
10.1016/S0959-8049(96)00510-2
10.1111/j.1742-7843.2006.pto_485.x
10.1158/0008-5472.CAN-03-2770
10.1146/annurev.med.53.082901.103929
10.1016/S0092-8674(00)81683-9
10.1248/bpb.27.1769
10.1158/1535-7163.MCT-07-0147
10.2174/092986709789104993
10.1016/S0304-3835(02)00025-3
10.1002/ijc.21893
10.3748/wjg.v16.i18.2235
10.1016/j.canlet.2007.12.004
10.1248/bpb.27.998
10.1007/s10541-005-0105-4
10.1016/j.lfs.2005.06.046
10.1007/s00109-008-0398-z
10.1093/jnci/djj234
10.1002/bit.260110607
10.1136/jcp.54.12.927
10.1093/jnci/86.20.1517
10.1054/drup.1999.0094
10.7326/0003-4819-91-5-710
10.1073/pnas.88.10.4328
10.1016/j.canlet.2007.06.014
10.3748/wjg.14.1491
10.1016/j.jhep.2006.08.012
10.1038/sj.bjc.6603127
10.1016/j.canlet.2010.12.015
10.1016/S0024-3205(98)00618-3
10.1002/hep.510260413
10.1016/j.biopha.2008.07.089
10.1055/s-2006-951748
10.1002/hep.21330
10.1159/000077991
10.1016/j.tox.2008.11.014
10.1021/bi001603q
10.1038/ng.2806
10.1186/1472-6750-5-12
10.1093/jnci/92.16.1295
10.1159/000151541
10.1038/sj.onc.1206945
ContentType Journal Article
Copyright Hahnvajanawong et al.; licensee BioMed Central Ltd. 2014
2014 Hahnvajanawong et al.; licensee BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly credited.
Copyright_xml – notice: Hahnvajanawong et al.; licensee BioMed Central Ltd. 2014
– notice: 2014 Hahnvajanawong et al.; licensee BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly credited.
DBID C6C
AAYXX
CITATION
NPM
3V.
7TM
7TO
7X7
7XB
8FI
8FJ
8FK
ABUWG
AFKRA
AZQEC
BENPR
CCPQU
DWQXO
FYUFA
GHDGH
H94
K9.
M0S
PHGZM
PHGZT
PIMPY
PKEHL
PQEST
PQQKQ
PQUKI
PRINS
7X8
5PM
DOI 10.1186/1475-2867-14-68
DatabaseName SpringerOpen Free (Free internet resource, activated by CARLI)
CrossRef
PubMed
ProQuest Central (Corporate)
Nucleic Acids Abstracts
Oncogenes and Growth Factors Abstracts
Health & Medical Collection
ProQuest Central (purchase pre-March 2016)
Hospital Premium Collection
Hospital Premium Collection (Alumni Edition)
ProQuest Central (Alumni) (purchase pre-March 2016)
ProQuest Central (Alumni)
ProQuest Central UK/Ireland
ProQuest Central Essentials
ProQuest Central
ProQuest One Community College
ProQuest Central Korea
Health Research Premium Collection
Health Research Premium Collection (Alumni)
AIDS and Cancer Research Abstracts
ProQuest Health & Medical Complete (Alumni)
ProQuest Health & Medical Collection
Proquest Central Premium
ProQuest One Academic (New)
Publicly Available Content Database
ProQuest One Academic Middle East (New)
ProQuest One Academic Eastern Edition (DO NOT USE)
ProQuest One Academic
ProQuest One Academic UKI Edition
ProQuest Central China
MEDLINE - Academic
PubMed Central (Full Participant titles)
DatabaseTitle CrossRef
PubMed
Publicly Available Content Database
Oncogenes and Growth Factors Abstracts
ProQuest One Academic Middle East (New)
ProQuest Central Essentials
ProQuest One Academic Eastern Edition
Nucleic Acids Abstracts
ProQuest Health & Medical Complete (Alumni)
ProQuest Central (Alumni Edition)
ProQuest One Community College
ProQuest Hospital Collection
Health Research Premium Collection (Alumni)
ProQuest Central China
ProQuest Hospital Collection (Alumni)
ProQuest Central
ProQuest Health & Medical Complete
Health Research Premium Collection
ProQuest One Academic UKI Edition
Health and Medicine Complete (Alumni Edition)
ProQuest Central Korea
AIDS and Cancer Research Abstracts
ProQuest Central (New)
ProQuest One Academic
ProQuest One Academic (New)
ProQuest Central (Alumni)
MEDLINE - Academic
DatabaseTitleList MEDLINE - Academic

Publicly Available Content Database
PubMed

Database_xml – sequence: 1
  dbid: C6C
  name: SpringerOpen Free (Free internet resource, activated by CARLI)
  url: http://www.springeropen.com/
  sourceTypes: Publisher
– sequence: 2
  dbid: NPM
  name: PubMed
  url: https://proxy.k.utb.cz/login?url=http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed
  sourceTypes: Index Database
– sequence: 3
  dbid: BENPR
  name: ProQuest Central
  url: https://www.proquest.com/central
  sourceTypes: Aggregation Database
DeliveryMethod fulltext_linktorsrc
Discipline Biology
EISSN 1475-2867
EndPage 68
ExternalDocumentID PMC4392878
oai_biomedcentral_com_1475_2867_14_68
3492902981
25866479
10_1186_1475_2867_14_68
Genre Journal Article
GroupedDBID ---
0R~
29B
2WC
4.4
53G
5GY
5VS
6J9
7X7
8FI
8FJ
AAFWJ
AAJSJ
AASML
ABDBF
ABUWG
ACGFO
ACGFS
ACIHN
ACIWK
ACMJI
ACPRK
ACUHS
ADBBV
ADRAZ
ADUKV
AEAQA
AENEX
AFKRA
AFPKN
AFRAH
AHBYD
AHMBA
AHSBF
AHYZX
ALMA_UNASSIGNED_HOLDINGS
AMKLP
AMTXH
AOIJS
BAPOH
BAWUL
BCNDV
BENPR
BFQNJ
BMC
BPHCQ
BVXVI
C6C
CCPQU
CS3
DIK
DU5
E3Z
EBD
EBLON
EBS
EJD
ESX
F5P
FYUFA
GROUPED_DOAJ
GX1
H13
HMCUK
HYE
IAO
IHR
ISR
ITC
KQ8
M48
M~E
O5R
O5S
OK1
OVT
P2P
PGMZT
PHGZM
PHGZT
PIMPY
PQQKQ
PROAC
PUEGO
RBZ
RNS
ROL
RPM
RSV
SBL
SOJ
TR2
TUS
UKHRP
W2D
WOQ
WOW
XSB
~8M
2VQ
88E
8R4
8R5
AAYXX
ALIPV
C1A
CITATION
IPNFZ
LGEZI
LOTEE
M1P
NADUK
NXXTH
PSQYO
RIG
NPM
3V.
7TM
7TO
7XB
8FK
AZQEC
DWQXO
H94
K9.
PKEHL
PQEST
PQUKI
PRINS
7X8
-56
-5G
-A0
-BR
ABVAZ
ACRMQ
ADINQ
AFGXO
AFNRJ
C24
FRP
5PM
ID FETCH-LOGICAL-b622t-e907d0504a19c62f022dc7094387456f02574050d6e4849fad7191c2d69ae0f43
IEDL.DBID 7X7
ISSN 1475-2867
IngestDate Thu Aug 21 13:37:21 EDT 2025
Wed May 22 07:11:58 EDT 2024
Fri Sep 05 04:09:15 EDT 2025
Sun Jun 29 16:58:59 EDT 2025
Thu Apr 03 07:06:22 EDT 2025
Thu Apr 24 23:02:53 EDT 2025
Tue Jul 01 02:41:37 EDT 2025
Sat Sep 06 07:29:31 EDT 2025
IsDoiOpenAccess true
IsOpenAccess true
IsPeerReviewed true
IsScholarly true
Issue 1
Keywords Isomorellin
Human cholangiocarcinoma cell lines
Synergistic effect
Forbesione
Doxorubicin
Apoptosis
Language English
License This article is published under license to BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly credited.
LinkModel DirectLink
MergedId FETCHMERGED-LOGICAL-b622t-e907d0504a19c62f022dc7094387456f02574050d6e4849fad7191c2d69ae0f43
Notes ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
content type line 14
content type line 23
OpenAccessLink https://www.proquest.com/docview/1622956880?pq-origsite=%requestingapplication%
PMID 25866479
PQID 1622956880
PQPubID 42567
PageCount 1
ParticipantIDs pubmedcentral_primary_oai_pubmedcentral_nih_gov_4392878
biomedcentral_primary_oai_biomedcentral_com_1475_2867_14_68
proquest_miscellaneous_1673078525
proquest_journals_1622956880
pubmed_primary_25866479
crossref_citationtrail_10_1186_1475_2867_14_68
crossref_primary_10_1186_1475_2867_14_68
springer_journals_10_1186_1475_2867_14_68
ProviderPackageCode CITATION
AAYXX
PublicationCentury 2000
PublicationDate 2014-10-24
PublicationDateYYYYMMDD 2014-10-24
PublicationDate_xml – month: 10
  year: 2014
  text: 2014-10-24
  day: 24
PublicationDecade 2010
PublicationPlace London
PublicationPlace_xml – name: London
– name: England
PublicationTitle Cancer cell international
PublicationTitleAbbrev Cancer Cell Int
PublicationTitleAlternate Cancer Cell Int
PublicationYear 2014
Publisher BioMed Central
BioMed Central Ltd
Publisher_xml – name: BioMed Central
– name: BioMed Central Ltd
References 10.1186/1475-2867-14-68-B13
10.1186/1475-2867-14-68-B35
10.1186/1475-2867-14-68-B12
10.1186/1475-2867-14-68-B56
10.1186/1475-2867-14-68-B11
10.1186/1475-2867-14-68-B33
10.1186/1475-2867-14-68-B55
10.1186/1475-2867-14-68-B10
10.1186/1475-2867-14-68-B31
10.1186/1475-2867-14-68-B53
10.1186/1475-2867-14-68-B52
10.1186/1475-2867-14-68-B51
10.1186/1475-2867-14-68-B50
10.1186/1475-2867-14-68-B19
10.1186/1475-2867-14-68-B18
10.1186/1475-2867-14-68-B17
10.1186/1475-2867-14-68-B39
10.1186/1475-2867-14-68-B16
10.1186/1475-2867-14-68-B15
10.1186/1475-2867-14-68-B37
10.1186/1475-2867-14-68-B36
10.1186/1475-2867-14-68-B3
10.1186/1475-2867-14-68-B2
10.1186/1475-2867-14-68-B1
10.1186/1475-2867-14-68-B24
10.1186/1475-2867-14-68-B46
10.1186/1475-2867-14-68-B23
10.1186/1475-2867-14-68-B44
10.1186/1475-2867-14-68-B21
10.1186/1475-2867-14-68-B43
10.1186/1475-2867-14-68-B42
10.1186/1475-2867-14-68-B9
10.1186/1475-2867-14-68-B29
10.1186/1475-2867-14-68-B8
10.1186/1475-2867-14-68-B7
10.1186/1475-2867-14-68-B27
10.1186/1475-2867-14-68-B49
10.1186/1475-2867-14-68-B6
10.1186/1475-2867-14-68-B26
10.1186/1475-2867-14-68-B5
10.1186/1475-2867-14-68-B25
10.1186/1475-2867-14-68-B47
17117343 - Planta Med. 2007 Jan;73(1):33-40
18248784 - Cancer Lett. 2008 Apr 18;262(2):214-22
1903539 - Proc Natl Acad Sci U S A. 1991 May 15;88(10):4328-32
11773296 - J Natl Cancer Inst Monogr. 2001;(30):72-9
10647931 - Cell. 2000 Jan 7;100(1):57-70
15958484 - Ann Oncol. 2005;16 Suppl 2:ii93-6
10075109 - Life Sci. 1999;64(9):763-74
9721092 - Science. 1998 Aug 28;281(5381):1309-12
18330936 - World J Gastroenterol. 2008 Mar 14;14(10):1491-7
15807663 - Biochemistry (Mosc). 2005 Feb;70(2):231-9
12429642 - Clin Cancer Res. 2002 Nov;8(11):3512-9
20458760 - World J Gastroenterol. 2010 May 14;16(18):2235-43
22972485 - Biol Pharm Bull. 2012;35(11):1914-25
17012222 - Carcinogenesis. 2007 Mar;28(3):632-8
16918721 - Basic Clin Pharmacol Toxicol. 2006 Aug;99(2):178-84
15516720 - Biol Pharm Bull. 2004 Nov;27(11):1769-74
19084572 - Toxicology. 2009 Feb 4;256(1-2):135-40
18804944 - Biomed Pharmacother. 2008 Nov;62(9):622-9
16570287 - Int J Cancer. 2006 Sep 1;119(5):1067-72
18070617 - Biochem Pharmacol. 2008 Mar 1;75(5):1083-92
11818492 - Annu Rev Med. 2002;53:615-27
17693016 - Cancer Lett. 2007 Oct 28;256(2):259-66
15150106 - Cancer Res. 2004 May 15;64(10):3517-24
15948244 - World J Gastroenterol. 2005 Jun 14;11(22):3392-7
17203872 - Acta Pol Pharm. 2006 Jul-Aug;63(4):321-4
11170436 - Biochemistry. 2001 Jan 30;40(4):1117-23
9328309 - Hepatology. 1997 Oct;26(4):884-90
496103 - Ann Intern Med. 1979 Nov;91(5):710-7
10973057 - Trends Biochem Sci. 2000 Sep;25(9):434-40
17876042 - Mol Cancer Ther. 2007 Sep;6(9):2429-40
21216092 - Cancer Lett. 2011 Feb 28;301(2):221-8
17069924 - J Hepatol. 2007 Feb;46(2):222-9
9274436 - Eur J Cancer. 1997 Apr;33(4):566-74
11504498 - Drug Resist Updat. 1999 Aug;2(4):271-273
10944550 - J Natl Cancer Inst. 2000 Aug 16;92(16):1295-302
15884115 - World J Gastroenterol. 2005 May 14;11(18):2748-53
5365804 - Biotechnol Bioeng. 1969 Nov;11(6):1101-10
24185513 - Nat Genet. 2013 Dec;45(12 ):1474-8
16788161 - J Natl Cancer Inst. 2006 Jun 21;98(12):873-5
7932806 - J Natl Cancer Inst. 1994 Oct 19;86(20):1517-24
16736026 - Br J Cancer. 2006 Jun 5;94(11):1751-8
15885144 - BMC Biotechnol. 2005 May 10;5:12
19747141 - Curr Med Chem. 2009;16(28):3775-96
18714155 - Chemotherapy. 2008;54(5):343-51
17006947 - Hepatology. 2006 Oct;44(4):1025-38
18777017 - J Mol Med (Berl). 2008 Dec;86(12 ):1367-77
11983155 - Cell. 2002 Apr;109 Suppl:S81-96
15256729 - Biol Pharm Bull. 2004 Jul;27(7):998-1003
14576849 - Oncogene. 2003 Oct 20;22(47):7414-30
19243472 - J Cell Mol Med. 2010 Mar;14(3):687-98
16257012 - Life Sci. 2006 Feb 9;78(11):1238-45
11729212 - J Clin Pathol. 2001 Dec;54(12):927-32
12430184 - Cancer Lett. 2002 Jul 8;181(1):95-107
15218306 - Oncology. 2004;66(3):167-79
References_xml – ident: 10.1186/1475-2867-14-68-B33
  doi: 10.1016/S0968-0004(00)01617-0
– ident: 10.1186/1475-2867-14-68-B5
  doi: 10.1016/S0959-8049(96)00510-2
– ident: 10.1186/1475-2867-14-68-B27
  doi: 10.1111/j.1742-7843.2006.pto_485.x
– ident: 10.1186/1475-2867-14-68-B10
  doi: 10.1158/0008-5472.CAN-03-2770
– ident: 10.1186/1475-2867-14-68-B43
  doi: 10.1146/annurev.med.53.082901.103929
– ident: 10.1186/1475-2867-14-68-B7
  doi: 10.1016/S0092-8674(00)81683-9
– ident: 10.1186/1475-2867-14-68-B37
  doi: 10.1248/bpb.27.1769
– ident: 10.1186/1475-2867-14-68-B24
  doi: 10.1158/1535-7163.MCT-07-0147
– ident: 10.1186/1475-2867-14-68-B18
  doi: 10.2174/092986709789104993
– ident: 10.1186/1475-2867-14-68-B39
  doi: 10.1016/S0304-3835(02)00025-3
– ident: 10.1186/1475-2867-14-68-B12
  doi: 10.1002/ijc.21893
– ident: 10.1186/1475-2867-14-68-B29
  doi: 10.3748/wjg.v16.i18.2235
– ident: 10.1186/1475-2867-14-68-B16
  doi: 10.1016/j.canlet.2007.12.004
– ident: 10.1186/1475-2867-14-68-B19
  doi: 10.1248/bpb.27.998
– ident: 10.1186/1475-2867-14-68-B46
  doi: 10.1007/s10541-005-0105-4
– ident: 10.1186/1475-2867-14-68-B21
  doi: 10.1016/j.lfs.2005.06.046
– ident: 10.1186/1475-2867-14-68-B23
  doi: 10.1007/s00109-008-0398-z
– ident: 10.1186/1475-2867-14-68-B1
  doi: 10.1093/jnci/djj234
– ident: 10.1186/1475-2867-14-68-B42
  doi: 10.1002/bit.260110607
– ident: 10.1186/1475-2867-14-68-B8
  doi: 10.1136/jcp.54.12.927
– ident: 10.1186/1475-2867-14-68-B31
  doi: 10.1093/jnci/86.20.1517
– ident: 10.1186/1475-2867-14-68-B49
  doi: 10.1054/drup.1999.0094
– ident: 10.1186/1475-2867-14-68-B6
  doi: 10.7326/0003-4819-91-5-710
– ident: 10.1186/1475-2867-14-68-B25
  doi: 10.1073/pnas.88.10.4328
– ident: 10.1186/1475-2867-14-68-B26
  doi: 10.1016/j.canlet.2007.06.014
– ident: 10.1186/1475-2867-14-68-B55
  doi: 10.3748/wjg.14.1491
– ident: 10.1186/1475-2867-14-68-B50
  doi: 10.1016/j.jhep.2006.08.012
– ident: 10.1186/1475-2867-14-68-B2
  doi: 10.1038/sj.bjc.6603127
– ident: 10.1186/1475-2867-14-68-B35
  doi: 10.1016/j.canlet.2010.12.015
– ident: 10.1186/1475-2867-14-68-B15
  doi: 10.1016/S0024-3205(98)00618-3
– ident: 10.1186/1475-2867-14-68-B9
  doi: 10.1002/hep.510260413
– ident: 10.1186/1475-2867-14-68-B51
  doi: 10.1016/j.biopha.2008.07.089
– ident: 10.1186/1475-2867-14-68-B36
  doi: 10.1055/s-2006-951748
– ident: 10.1186/1475-2867-14-68-B52
  doi: 10.1002/hep.21330
– ident: 10.1186/1475-2867-14-68-B3
  doi: 10.1159/000077991
– ident: 10.1186/1475-2867-14-68-B17
  doi: 10.1016/j.tox.2008.11.014
– ident: 10.1186/1475-2867-14-68-B47
  doi: 10.1021/bi001603q
– ident: 10.1186/1475-2867-14-68-B53
  doi: 10.1038/ng.2806
– ident: 10.1186/1475-2867-14-68-B56
  doi: 10.1186/1472-6750-5-12
– ident: 10.1186/1475-2867-14-68-B13
  doi: 10.1093/jnci/92.16.1295
– ident: 10.1186/1475-2867-14-68-B11
  doi: 10.1159/000151541
– ident: 10.1186/1475-2867-14-68-B44
  doi: 10.1038/sj.onc.1206945
– reference: 16918721 - Basic Clin Pharmacol Toxicol. 2006 Aug;99(2):178-84
– reference: 11729212 - J Clin Pathol. 2001 Dec;54(12):927-32
– reference: 1903539 - Proc Natl Acad Sci U S A. 1991 May 15;88(10):4328-32
– reference: 16736026 - Br J Cancer. 2006 Jun 5;94(11):1751-8
– reference: 7932806 - J Natl Cancer Inst. 1994 Oct 19;86(20):1517-24
– reference: 14576849 - Oncogene. 2003 Oct 20;22(47):7414-30
– reference: 15884115 - World J Gastroenterol. 2005 May 14;11(18):2748-53
– reference: 12429642 - Clin Cancer Res. 2002 Nov;8(11):3512-9
– reference: 16788161 - J Natl Cancer Inst. 2006 Jun 21;98(12):873-5
– reference: 10973057 - Trends Biochem Sci. 2000 Sep;25(9):434-40
– reference: 17117343 - Planta Med. 2007 Jan;73(1):33-40
– reference: 16257012 - Life Sci. 2006 Feb 9;78(11):1238-45
– reference: 17069924 - J Hepatol. 2007 Feb;46(2):222-9
– reference: 11818492 - Annu Rev Med. 2002;53:615-27
– reference: 15218306 - Oncology. 2004;66(3):167-79
– reference: 18804944 - Biomed Pharmacother. 2008 Nov;62(9):622-9
– reference: 5365804 - Biotechnol Bioeng. 1969 Nov;11(6):1101-10
– reference: 15885144 - BMC Biotechnol. 2005 May 10;5:12
– reference: 21216092 - Cancer Lett. 2011 Feb 28;301(2):221-8
– reference: 22972485 - Biol Pharm Bull. 2012;35(11):1914-25
– reference: 19747141 - Curr Med Chem. 2009;16(28):3775-96
– reference: 15256729 - Biol Pharm Bull. 2004 Jul;27(7):998-1003
– reference: 17203872 - Acta Pol Pharm. 2006 Jul-Aug;63(4):321-4
– reference: 17693016 - Cancer Lett. 2007 Oct 28;256(2):259-66
– reference: 11504498 - Drug Resist Updat. 1999 Aug;2(4):271-273
– reference: 18330936 - World J Gastroenterol. 2008 Mar 14;14(10):1491-7
– reference: 12430184 - Cancer Lett. 2002 Jul 8;181(1):95-107
– reference: 15516720 - Biol Pharm Bull. 2004 Nov;27(11):1769-74
– reference: 15150106 - Cancer Res. 2004 May 15;64(10):3517-24
– reference: 20458760 - World J Gastroenterol. 2010 May 14;16(18):2235-43
– reference: 10647931 - Cell. 2000 Jan 7;100(1):57-70
– reference: 19084572 - Toxicology. 2009 Feb 4;256(1-2):135-40
– reference: 15948244 - World J Gastroenterol. 2005 Jun 14;11(22):3392-7
– reference: 496103 - Ann Intern Med. 1979 Nov;91(5):710-7
– reference: 10075109 - Life Sci. 1999;64(9):763-74
– reference: 18248784 - Cancer Lett. 2008 Apr 18;262(2):214-22
– reference: 11773296 - J Natl Cancer Inst Monogr. 2001;(30):72-9
– reference: 17012222 - Carcinogenesis. 2007 Mar;28(3):632-8
– reference: 18070617 - Biochem Pharmacol. 2008 Mar 1;75(5):1083-92
– reference: 18777017 - J Mol Med (Berl). 2008 Dec;86(12 ):1367-77
– reference: 11170436 - Biochemistry. 2001 Jan 30;40(4):1117-23
– reference: 9274436 - Eur J Cancer. 1997 Apr;33(4):566-74
– reference: 15807663 - Biochemistry (Mosc). 2005 Feb;70(2):231-9
– reference: 11983155 - Cell. 2002 Apr;109 Suppl:S81-96
– reference: 10944550 - J Natl Cancer Inst. 2000 Aug 16;92(16):1295-302
– reference: 15958484 - Ann Oncol. 2005;16 Suppl 2:ii93-6
– reference: 17006947 - Hepatology. 2006 Oct;44(4):1025-38
– reference: 18714155 - Chemotherapy. 2008;54(5):343-51
– reference: 19243472 - J Cell Mol Med. 2010 Mar;14(3):687-98
– reference: 17876042 - Mol Cancer Ther. 2007 Sep;6(9):2429-40
– reference: 9328309 - Hepatology. 1997 Oct;26(4):884-90
– reference: 24185513 - Nat Genet. 2013 Dec;45(12 ):1474-8
– reference: 16570287 - Int J Cancer. 2006 Sep 1;119(5):1067-72
– reference: 9721092 - Science. 1998 Aug 28;281(5381):1309-12
SSID ssj0017860
Score 2.1151295
Snippet Background Chemotherapy for advanced cholangiocarcinoma (CCA) is largely ineffective, but innovative combinations of chemotherapeutic agents and natural...
Chemotherapy for advanced cholangiocarcinoma (CCA) is largely ineffective, but innovative combinations of chemotherapeutic agents and natural compounds...
Doc number: 68 Abstract Background: Chemotherapy for advanced cholangiocarcinoma (CCA) is largely ineffective, but innovative combinations of chemotherapeutic...
BACKGROUND: Chemotherapy for advanced cholangiocarcinoma (CCA) is largely ineffective, but innovative combinations of chemotherapeutic agents and natural...
SourceID pubmedcentral
biomedcentral
proquest
pubmed
crossref
springer
SourceType Open Access Repository
Aggregation Database
Index Database
Enrichment Source
Publisher
StartPage 68
SubjectTerms Biomedical and Life Sciences
Biomedicine
Cancer Research
Cell Biology
Cell cycle
Medical research
Mortality
Primary Research
Studies
SummonAdditionalLinks – databaseName: Scholars Portal Journals: Open Access
  dbid: M48
  link: http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwfV1La9wwEBZpQqGX0qQvt0lRoYf24NRW9SSEEEpCCKSXdiE3YVt2s7C1tutdyN760zsj25s6u83NiyX0mtF830r-hpAPKJGFSBtJDhAUgftgmVexEhXYjykqHnQKrr7JixG_vBbXd-mAuglsNlI7zCc1mk0Ob38vT8Dhj4PDa_k55UrETIPHpzyW-hHZgbAkkYld8bsjBaVl0mn7bKh073v3yTBMrWHP9SuU985RQ3g6f0aedriSnraGsEu2ynqPPG4zTS6fkz_fl_iRX1Blpt0dDuorOm483rRFYW6a1Y4ChMVMAb4uKf5DS52_9bNFjsfv1EORqZ_OfTNuKFD5VncWnmhI9EfDXNY_xxAdZ1De_8ooHgtQBLLNCzI6P_vx9SLuki_EuWRsHpfAml0iEp6lppCsgljvCoX3EFEgX8JvoQDsJU6WXHNTZU4B9SuYkyYrk4p_eUm2a-jtawJtOZdmLOF5YYCumlyniXHGAfLSIpNFRI4Gc2-nrdCGRenr4RvwQosrZ3Hl4MlKHZHDfqVs0emaY3qNiQ38Rsv1Ch9XFfqW_lt0v19625umTSWmQJew8UXk_eo1eCXOaVaXfoFlYOdUWjARkVetpazaYkJLyZWJiBrY0GDYwzf1-CYofwN6BIYL3frUW9s_3do8hDcPD-EteQIQkGM0ZnyfbM9ni_IAYNY8fxfc5y-MPSaT
  priority: 102
  providerName: Scholars Portal
– databaseName: SpringerOpen Free (Free internet resource, activated by CARLI)
  dbid: C6C
  link: http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwlV1La9wwEBZpQqGX0iZ9OI-iQg_pwa2tSCOJnkJoCIHk0gZyE7Zltwuptax3obnlp2dG9i5xNj30ZqMRki2N5huN9A1jn4gii5A2OTnooChaB-uySbVqcP7YqpGRp-DiEs6u5Pm1uh5IkuguzMP4fW7gay61SoVBbc5lCuYZ21L5EcSoLJyswgXaQDbw9jxR6dFd9puxCVrDlevHIx_FSKPpOX3FXg6YkR_3g_yabdTtNnveZ5G83WF3P27pAl9kXObD-QweGj7pAp2iJdJtXrSeIzylLAChrTntvnIf_obZoqTQOg8oMg3TeegmHUc3veeUxScek_jx6AK3vyZo-WYoH_4UnLb8OYHU7g27Ov3-8-QsHRIrpCUIMU9r9Ih9pjJZ5LYC0aAd95WmM4ZEfg_4rjQCucxDLY20TeE1unWV8GCLOmvk0Vu22WJv3zNsy_u8EJksK4uuqC1NnllvPaIqowqoEvZt9O_dtCfRcERrPS5BDXM0co5GDp8cmIR9WY6UqwbOckqdceOi72JgvcLhqsKypX-K7i-H3g1627kcKL054KKWsI-rYtQ4-qdFW4cFyeCqqI0SKmHv-pmyaksoAyC1TZgezaHRZ49L2snvyOqNyBC9V-zW5-Vse9Ctpz9h9z9k99gLxHqSzK6Q-2xzPlvUB4in5uWHqEv3Bh8bcA
  priority: 102
  providerName: Springer Nature
Title Synergistic effects of isomorellin and forbesione with doxorubicin on apoptosis induction in human cholangiocarcinoma cell lines
URI https://link.springer.com/article/10.1186/1475-2867-14-68
https://www.ncbi.nlm.nih.gov/pubmed/25866479
https://www.proquest.com/docview/1622956880
https://www.proquest.com/docview/1673078525
http://dx.doi.org/10.1186/1475-2867-14-68
https://pubmed.ncbi.nlm.nih.gov/PMC4392878
Volume 14
hasFullText 1
inHoldings 1
isFullTextHit
isPrint
link http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwfV3da9RAEB-0RfBF_DZajxV80IfYJO5X8EHs0VKEFqkWDl-WJJvUg5o9L3dg3_zTndlsTuOpLyFhN-zHzM7H7uxvAJ4TRBZZ2uTkoIMiSA7WZRMr0SD_5FXDPU7Byak8PufvZ2IWNty6EFY5yEQvqK2raI98P5WUeFoiu71dfIspaxSdroYUGtdh10OXIT-r2cbhSpWWSYDzSbXcT7kScaZRMqQ8JmzV0RX3y7Fm2jI3t6Mm_zg69Rrp6DbcCqYke9fT_g5cq9u7cKNPLnl1D358vKJ7fR6ImYWwDeYaNu8cBdcSFjcrWsvQaqXkAK6tGW3KMuu-u-W6pBN35rDKwi1Wrpt3DL33HmoW35jP7ce8Z9xezFEhLrG--1owOglgZLt29-H86PDT9DgO-RbiEid3FdfoKNtEJLxI80pmDap3WykKPSRMfInfQqF9l1hZc83zprAKvb0qszIv6qThrx_ATou9fQTYlrVpkSW8rHL0UPNSp0luc4vGlhaFrCJ4M5p7s-ixNQyhXY9LkAkMUc4Q5fDNSB3Bq4FSpgpQ5pRR49J4l0bL7R9ebH4YWvpn1b2B9CYs5878Yr4Inm2KcSHSnBZt7dZUB4Wl0iITETzsOWXTVia0lFzlEagRD42GPS5p51882DcajOjUYrdeDtz2W7f-PoTH_x_CE7iJVh8nBZzxPdhZLdf1U7SsVuXEL58J7B4cnn44w6-pnE78LgU-T7jG59nB559lkymF
linkProvider ProQuest
linkToHtml http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwtV1Lb9QwEB6VrRBcEG_SFjASSHAITVLbcYQQ4tFqS9sVglbqzSRxQiO18bLZVdkbv4jfyEweC2GBW2-J7MR2ZjyPzPgbgMcEkUWWNjk56KAIkoNZkruhyJF_ojTnNU7BwUgOj_j7Y3G8Aj-6szCUVtnJxFpQG5vSP_JNX1LhaYns9mr81aWqURRd7UpoNGyxl83P0WWrXu6-Q_o-CYKd7cO3Q7etKuAm-Iqpm6E7aDzh8diPUhnkqMRMGlKCHSG_S7wXIVoxnpEZVzzKYxOiT5MGRkZx5uV8C997CVY5nWgdwOqb7dGHj4u4Raik1wII-Upu-jwUbqBQFvncJTTX3qH6074uXDJwl_M0_wjW1jpw5zpca41X9rrhthuwkpU34XJTznJ-C75_mtNJwhr6mbWJIszmrKgspfMS-jeLS8PQTqZyBLbMGP0GZsZ-s5NZQjF-ZrHL2I6ntioqVpSmAbfFK1ZXE2S1L15-KVAFT7C_PYsZxR4YWcvVbTi6EFrcgUGJs70HOJYxfhx4PEkj9ImjRPleZCKD5p0SsUwdeNH79nrcoHlowtfutyDbaaKcJsrhlZbKgecdpXTagqdTDY9TXTtRSi4_8HTxQDfSP7tudKTXrQCp9C92d-DRohm3Pn3TuMzsjPqgeA6VCIQDdxtOWYwVCCUlDyMHwh4P9ZbdbymLkxpeHE1UdKNxWs86bvttWn9fwtr_l_AQrgwPD_b1_u5obx2uos3JSf0HfAMG08ksu4923TR50G4mBp8vev_-BImJYAU
linkToPdf http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwlV1Lb9RADLagCMQFlVcJFBgkDnAITYZ5ilNVWJVXhQSVehslmQRWKpnVJivRW386dh6rplsO3LIaj2YS22N77fkM8JIgssjTpiAHAxRJ52CZV7GWFcqPLSrR4RR8PVKHx-LTiTwZanOasdp9TEn2dxoIpalu9xa-6lXcqL1UaBlzgzqeiliZ63BDkN2jXK06WCcRtFHJgOZzxaRLN9xPp4Zpw9vcLJq8lDntDNJsG-4MniTb71l_F66V9T242feWPLsP59_P6Fpfh8PMhqoNFio2bwLV1hIUN8tqz9Bppd4AoS4Z_SfLfPgTlqucEu4sIMkiLNrQzBuGwXuPNItPrGvtx7rAuP45R3u4RPrwO2OUCGDkujYP4Hj24cfBYTy0W4hzxXkblxgn-0QmIkttoXiF1t0XmioPCRJf4W-p0b1LvCqFEbbKvMZgr-Be2axMKvH2IWzVuNtHgGt5n2Y8EXlhMUC1uUkT661HX8vITBURvJt8e7fooTUcgV1PR1AEHHHOEefwySkTwZuRU64YkMypocap6yIaozYnvFpPGFf6J-nuyHo3aHPjUkVNzxUedRG8WA-jHtI3zeoyrIgGz0ptJJcR7PSSsl6LS6OU0DYCPZGhyWtPR-r5rw7rG_1FjGlxW69Habuwratf4fF_0D6HW9_ez9yXj0efn8BtdAYF2WUudmGrXa7Kp-hwtfmzTq3-AllSJqQ
openUrl ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Synergistic+effects+of+isomorellin+and+forbesione+with+doxorubicin+on+apoptosis+induction+in+human+cholangiocarcinoma+cell+lines&rft.jtitle=Cancer+cell+international&rft.au=Hahnvajanawong%2C+Chariya&rft.au=Wattanawongdon%2C+Wareeporn&rft.au=Chomvarin%2C+Chariya&rft.au=Anantachoke%2C+Natthinee&rft.date=2014-10-24&rft.pub=BioMed+Central&rft.eissn=1475-2867&rft.volume=14&rft_id=info:doi/10.1186%2F1475-2867-14-68&rft.externalDocID=3492902981
thumbnail_l http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=1475-2867&client=summon
thumbnail_m http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=1475-2867&client=summon
thumbnail_s http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=1475-2867&client=summon